U.S. FDA Approved CAPVAXIVEâ„¢ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
| | | | |

U.S. FDA Approved CAPVAXIVEâ„¢ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults

On Jun. 17, 2024, Merck announced that the U.S. Food and Drug Administration (FDA) had approved CAPVAXIVEâ„¢ (Pneumococcal…

CIRM awarded $53 million to clinical research in heart failure and cystic fibrosis, supporting 10 translational projects
| | | | | | | |

CIRM awarded $53 million to clinical research in heart failure and cystic fibrosis, supporting 10 translational projects

On May 30, 2024, the California Institute for Regenerative Medicine (CIRM) announced it had awarded $53 million to…